BiotechTube
Home/Pipeline/TNB-486

TNB-486

B-cell malignancies

Phase 1Active

Key Facts

Indication
B-cell malignancies
Phase
Phase 1
Status
Active
Company
Ancora Bio

About Ancora Bio

Ancora Biotech is a strategic holding entity formed by former executives and investors of Teneobio to advance a portfolio of three multi-specific antibody programs. Its most advanced asset, TNB-486 (anti-CD19xCD3), is in Phase 1 for B-cell malignancies, while two preclinical programs target CD38 for metabolic diseases and HBVxCD3 for a functional cure of chronic hepatitis B. The company's model involves spinning out assets into dedicated subsidiaries (TeneoTwo, TeneoFour, TeneoTen) while centralizing oversight of manufacturing and clinical development. Key financial backers include Lightspeed Venture Partners and Sutter Hill Ventures.

View full company profile

Therapeutic Areas

OncologyMetabolic DiseasesInfectious Diseases

Other B-cell malignancies Drugs

DrugCompanyPhase
CAR-T Program (Hematological)XellSmartPhase 1
BAFFR Allo CAR-NK CellsPeproMene BioPre-clinical
IKS03Iksuda TherapeuticsClinical
docirbrutinib (AS-1763)Carna BiosciencesPhase 1b
AbivertinibSorrento TherapeuticsPhase 1/2
Kymriah® (tisagenlecleucel)NovartisApproved
KITE-363Gilead SciencesPhase 1/2
HSK29116Haisco Pharmaceutical GroupPhase I/II
TG-1701TG TherapeuticsPhase 1
TG-1801TG TherapeuticsPhase 1
REC-3565Recursion PharmaceuticalsPhase 1
Plamotamab (XmAb®13676)XencorPhase 2